Morgan Stanley raised the firm’s price target on Edwards Lifesciences (EW) to $81 from $75 and keeps an Equal Weight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Cautious Outlook for Edwards Lifesciences Amidst TAVR Sales Challenges and Market Share Concerns
- Edwards Lifesciences’ PROGRESS Trial: A Game-Changer for Aortic Stenosis Treatment?
- Edwards Lifesciences Launches MITRIS Valve Study in China: A Potential Market Game-Changer
- Edwards Lifesciences initiated with a Buy at Argus
- Edwards Lifesciences’ SAPIEN X4 Valve Study: A Potential Game-Changer in Heart Valve Treatment